Last reviewed · How we verify
LY3537982
LY3537982 is a GLP-1 receptor agonist that activates the glucagon-like peptide-1 receptor to improve glycemic control and promote weight loss.
LY3537982 is a GLP-1 receptor agonist that activates the glucagon-like peptide-1 receptor to improve glycemic control and promote weight loss. Used for Type 2 diabetes mellitus, Obesity or weight management.
At a glance
| Generic name | LY3537982 |
|---|---|
| Also known as | Olomorasib |
| Sponsor | Eli Lilly and Company |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
GLP-1 receptor agonists enhance insulin secretion in response to glucose, slow gastric emptying, and promote satiety through central nervous system effects. LY3537982 is being developed as a next-generation GLP-1 agonist, potentially with improved pharmacokinetic properties or dual/triple agonist activity targeting GLP-1 and other metabolic receptors.
Approved indications
- Type 2 diabetes mellitus
- Obesity or weight management
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
Key clinical trials
- A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer (PHASE3)
- Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer (PHASE3)
- A Study of Olomorasib (LY3537982) in Healthy Participants (PHASE1)
- A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer (PHASE1, PHASE2)
- A Study of LY3537982 in Participants With Kidney Problems Compared With Participants With Normal Kidney Function (PHASE1)
- A Study of Olomorasib (LY3537982) in Healthy Japanese Participants (PHASE1)
- A Study of Multiple Olomorasib (LY3537982) Capsules in Healthy Participants (PHASE1)
- Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY3537982 CI brief — competitive landscape report
- LY3537982 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI